am I the only one who found tirzepatide harder than the injections
am I the only one who found tirzepatide harder than the injections. I am not trying to be the "source?" guy. I would just like a source.
The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.
Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.
Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.
switching from sema is not a dose conversion, there is no clean equivalence
Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.
Did you come to this from sema, and if so how long was the gap?
Switching from semaglutide, since three people asked in this thread alone.
There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.
None of that is a recommendation. It is what the threads say, and the threads are not a clinic.
the four-week step schedule is the label, not folklore
Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.
Same experience with the appetite effect being flatter across the week rather than front-loaded.
Yes — 10mg being a genuine landing place for a lot of people is underrated. There is no medal for 15.
Week 89 was the first time the scale moved after a five-week stall. I changed nothing in that window.
Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.
The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.
The thing nobody warned me about was how much of this is logistics — storing it, remembering it, the same day every week.
I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your reflux pattern is a guess.
Trial identifiers corrected in the title. SURMOUNT and SURPASS are different programmes.
That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.
Correction to my own post above — I said 5mg and I have been on 2.5mg since the spring. Same argument, wrong number.
Not sure that follows. You went up a step and changed your training in the same fortnight.
SURMOUNT-1 landed around 21% at 72 weeks on the top arm
Which week did the appetite change actually land for you?
Which week did the appetite change actually land for you?
Saving this one. It is the clearest statement of the stall problem I have read here.
Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.
It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.
a lot of people plateau nicely at 10mg and never need 15
the injection-site soreness profile is genuinely gentler than people expect coming from sema
Does injection-site soreness follow the day after the shot, or is it spread across the week?
This matches mine. Milder fatigue than I expected, and what there was settled inside a fortnight of each step.
Disagree with the conversion table. There is no validated equivalence between the two molecules and posting one as though there is does real damage.
- 1The distribution matters more than the mean. In the trial population the…8 comments in this branch · started by u/titration_marshal
- 2It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part…6 comments in this branch · started by u/vito_chowdhury